Ivonescimab 20 mg/kg
2025-1970
Phase 2 small_molecule active
Quick answer
Ivonescimab 20 mg/kg for Nasopharyngeal Carcinoma (NPC) is a Phase 2 program (small_molecule) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Hospital Authority, Hong Kong
- Indication
- Nasopharyngeal Carcinoma (NPC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active